ANVISA Approves MagicTouch Sirolimus-Coated Balloon: Market Impact in Brazil

Key Takeaways

• First-in-market: ANVISA granted commercial approval for MagicTouch on September 12, 2025, marking the first sirolimus-coated balloon (SCB) approved for coronary artery disease in Brazil (Concept Medical press release).
• Clinical evidence: The device is supported by the TRANSFORM I trial (NCT03913832), which enrolled 121 subjects, and the ongoing MAGICAL SV trial (NCT06271590), targeting 1,605 subjects across North America, Europe, and South America.
• Market size: Brazil performs approximately 200,000 percutaneous coronary intervention (PCI) procedures annually, representing Latin America's largest cardiac device market.
• Technology: MagicTouch uses proprietary Nanolute technology for controlled sirolimus delivery without leaving permanent metal implants in the vessel.
• Access pathway: Commercial approval enables marketing and distribution; SUS reimbursement requires separate health economic negotiations.

What Is the MagicTouch Device?

The MagicTouch sirolimus-coated balloon is a percutaneous coronary intervention (PCI) device developed by Concept Medical. It delivers sirolimus—an anti-proliferative immunosuppressant—directly to coronary artery lesions during balloon angioplasty. Sirolimus has been established in cardiology for over two decades as an effective agent in preventing restenosis, the recurrent narrowing of coronary arteries following intervention.

The device combines a semi-compliant balloon platform with a proprietary coating that elutes sirolimus at the lesion site. Unlike drug-eluting stents (DES), which remain permanently in the vessel, the sirolimus-coated balloon is withdrawn after intervention. This approach may offer advantages in small-vessel disease, bifurcation lesions, or scenarios where stent placement is contraindicated or technically challenging.

MagicTouch uses Nanolute technology, Concept Medical's proprietary drug delivery platform. This technology enables controlled release of sirolimus to the vessel wall, targeting neointimal hyperplasia—the pathological tissue growth that drives restenosis.

What Clinical Evidence Supports the Device?

The MagicTouch device has been evaluated in multiple clinical studies. The TRANSFORM I trial (NCT03913832) was a prospective, multinational, multicenter, randomized study comparing MagicTouch to the SeQuent Please Neo paclitaxel-coated balloon (B. Braun) for treating de novo coronary artery lesions in small vessels (less than or equal to 2.75 mm). The study enrolled 121 subjects and was completed in September 2023.

The primary endpoint was net gain in millimeters at 6-month follow-up. Subjects underwent optical coherence tomography (OCT) post pre-dilatation to guide drug-coated balloon treatment. The study design reflected real-world clinical practice where vessel sizing and lesion assessment guide interventional strategy.

The ongoing MAGICAL SV trial (NCT06271590) is a pivotal study recruiting up to 1,605 subjects across approximately 50 sites in North America, with potential European and South American participation. This trial evaluates safety and efficacy in small vessels (less than or equal to 2.75 mm), with target lesion failure (TLF) at 12 months as the primary endpoint. The study began in May 2025 and has a primary completion date of November 2028.

When Did ANVISA Grant Approval?

ANVISA (Agência Nacional de Vigilância Sanitária), Brazil's National Health Surveillance Agency, granted commercial approval for the MagicTouch sirolimus-coated balloon on September 12, 2025. The approval was announced by Concept Medical in a press release on the same date.

This approval followed the device's CE mark certification, which Concept Medical obtained on October 16, 2019 for the MagicTouch product line. The CE certification covers multiple indications including peripheral arterial disease, erectile dysfunction, and arteriovenous fistula applications.

ANVISA's approval process for cardiovascular devices typically involves assessment of biocompatibility, performance testing, clinical evidence, and manufacturing quality standards aligned with international device regulations and ISO standards. The approval enables Concept Medical to market and distribute the device within Brazil's healthcare system.

How Large Is the Brazilian Coronary Intervention Market?

Brazil represents Latin America's largest market for coronary intervention devices. According to Concept Medical's data, Brazil performs approximately 200,000 PCI procedures annually. Latin America as a whole conducts nearly 500,000 PCI procedures each year.

The coronary intervention market has been dominated by drug-eluting stent manufacturers including Abbott, Boston Scientific, and Medtronic. Sirolimus-coated balloon platforms remain a niche segment compared with stent-based interventions. However, they offer clinical differentiation in specific anatomical and patient scenarios.

The table below compares key device categories in the Brazilian coronary intervention market:

Coronary Intervention Device Categories in Brazil

Device Category	Primary Mechanism	Permanent Implant	Key Players
Drug-eluting stents (DES)	Scaffold + drug delivery	Yes	Abbott, Boston Scientific, Medtronic
Paclitaxel-coated balloons	Drug delivery only	No	B. Braun, Philips
Sirolimus-coated balloons	Drug delivery only	No	Concept Medical (first ANVISA-approved)
Bare-metal stents	Scaffold only	Yes	Various manufacturers

What Does ANVISA Approval Mean for Access?

ANVISA's commercial approval authorizes Concept Medical to market and distribute the MagicTouch device within Brazil's healthcare system. However, patient access depends on separate reimbursement decisions by SUS (Sistema Único de Saúde, Brazil's Unified Health System) and private insurance bodies.

Approval does not guarantee coverage. Health economic assessments and pricing negotiations with Brazilian health authorities will determine whether the device is reimbursed in public hospitals or remains available primarily through private sector channels. Device pricing in Brazil typically reflects manufacturing costs, regulatory compliance expenses, and competitive positioning relative to established alternatives.

Patients in private healthcare settings may gain access more rapidly than those dependent on SUS coverage. Concept Medical has indicated it is pursuing ANVISA approval for its wider drug-coated balloon (DCB) and drug-eluting stent (DES) portfolio, suggesting a broader commercial strategy for the Brazilian market.

What Are the Technical Specifications?

The MagicTouch sirolimus-coated balloon is indicated for patients with coronary artery disease who require revascularization, particularly in scenarios where balloon angioplasty alone or stent placement may present clinical limitations. The device targets lesions in native coronary arteries with visually estimated diameters of less than 2.75 mm and length up to 34.0 mm.

The device's mechanism targets neointimal hyperplasia—the pathological tissue growth that drives restenosis—by delivering sirolimus's anti-proliferative effects locally at the intervention site. This targeted delivery aims to reduce the risk of recurrent vessel narrowing while avoiding the long-term complications associated with permanent metal implants.

Professor Dr. Alexandre Abizaid, Director of Interventional Cardiology at Instituto do Coração in São Paulo, commented on the approval: "Great news to hear that ANVISA has approved the use of the first Sirolimus Coated Balloon, MagicTouch, in Brazil. Backed by strong clinical trials and innovative technology, MagicTouch will surely provide a safer alternative to treat patients with coronary obstructions."

What Is the Regulatory Pathway in Other Markets?

ANVISA's approval is specific to Brazil and does not automatically extend to other Latin American markets. Concept Medical would require separate regulatory submissions to COFEPRIS in Mexico, INVIMA in Colombia, and other national authorities for market access in additional countries.

Regulatory timelines and requirements vary by jurisdiction. However, ANVISA approval may facilitate discussions with other Latin American regulators by providing evidence of safety and efficacy review by a major regional authority. The company's CE mark certification also supports regulatory applications in markets that recognize European medical device standards.

The United States market requires FDA approval. Concept Medical has not yet announced FDA clearance for the MagicTouch coronary device, though the MAGICAL SV trial includes North American sites and may support a future FDA submission.

Frequently Asked Questions

Primary Sources

1. Concept Medical. "ANVISA Grants Commercial Approval to Concept Medical's MagicTouch Sirolimus-Coated Balloon for CAD in Brazil." Press release. September 12, 2025. https://www.conceptmedical.com/press_release/anvisa-grants-commercial-approval-to-concept-medicals-magictouch-sirolimus-coated-balloon-for-cad-in-brazil/
2. ClinicalTrials.gov. "TReAtmeNt of Small Coronary Vessels: MagicTouch Sirolimus Coated Balloon (TRANSFORM I)." NCT03913832. Status: Completed. August 2020–September 2023. Enrollment: 121 subjects. https://clinicaltrials.gov/study/NCT03913832
3. ClinicalTrials.gov. "MagicTouch Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels (MAGICAL SV)." NCT06271590. Status: Recruiting. May 2025–November 2031 (estimated). Enrollment: 1,605 subjects (target). https://clinicaltrials.gov/study/NCT06271590
4. Concept Medical. "Concept Medical is Granted CE Certification for Sirolimus Coated MagicTouch Group of Products." Press release. October 16, 2019. https://www.conceptmedical.com/press_release/sirolimus-coated-magictouch-group/
5. Abizaid A. (Instituto do Coração, São Paulo). Expert commentary included in Concept Medical ANVISA approval press release. September 12, 2025.